Knowledge on rare diseases and orphan drugs
COVID-19 & Rare diseases
Rare Diseases Resources for Refugees/Displaced Persons
Search for a rare disease
Autosomal dominant generalized epidermolysis bullosa simplex, severe form
Epidermolysis bullosa simplex, Dowling-Meara type (EBS-DM) is a basal subtype of epidermolysis bullosa simplex (EBS) characterized by the presence of generalized vesicles and small blisters in grouped or arcuate configuration.
ORPHA:79396
Classification level: Disorder
- Epidermolysis bullosa simplex, Dowling-Meara type
- Autosomal dominant generalized EBS, severe form
- Epidermolysis bullosa simplex herpetiformis
Prevalence: <1 / 1 000 000
Inheritance: Autosomal dominant
Age of onset: Neonatal
Worldwide prevalence is unknown but reported prevalence in Scotland is 1/1,700,000.
Onset is usually at birth with large, frequently hemorrhagic blisters. After the neonatal period, the lesions take the typical herpetiform (or herpes-like) clustering with central healing pattern. Blister formation gradually reduces starting from late childhood. By childhood, most patients begin to develop confluent thickening and hyperkeratosis (keratoderma) of the palms and soles which may partially resolve in some patients during mid- to late-adulthood. Along with blisters, skin findings commonly include mild atrophic scarring and post-inflammatory pigmentation, nail shedding and nail dystrophy, as well as occasional milia formation. Lesions may improve in some patients in case of fever, unlike other forms of EB in which warmer weather exacerbates disease activity. The reason for this is unknown. Extracutaneous complications can occur including oral cavity blistering, constipation and, rarely, tracheolaryngeal compromise.
EBS-DM is caused by dominant negative mutations within either the KRT5 (12q13.13) or KRT14 (17q12-q21) genes, encoding keratin 5 and keratin 14, respectively.
Transmission is autosomal dominant and sporadic cases are frequent.
EBS-DM is frequently associated with marked morbidity in infancy and early childhood and, in rare cases, may result in death during early infancy. Patients also have a markedly increased risk of basal cell carcinoma by mid-adulthood (cumulative risk of 44% by age 55).
Last update: May 2012 - Expert reviewer(s): Pr Giovanna ZAMBRUNO
: produced/endorsed by ERN(s)
: produced/endorsed by FSMR(s)
General public
Guidelines
Disease review articles
Disability
Further information on this disease
Patient-centred resources for this disease
Research activities on this disease
- Research project(s) (45)
- Clinical trial(s) (8)
- Biobank(s) (8)
- Registry(ies) (25)
- Network of experts (4)
Newborn screening